

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: PANGENOMIC HEALTH INC. (the "Issuer").

Trading Symbol: NARA

Number of Outstanding Listed Securities: 25,700,276 (as at April 30, 2026)

Date: May 6, 2026

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

PanGenomic Health Inc. is a precision health Issuer that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Our initial focus is on mental health. As a British Columbia benefit Issuer, the Issuer's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies alternative health solutions tailored to the health profile of each individual.

During the month of April 2026, the Issuer continued with its general and corporate activities of the business.

2. **Provide a general overview and discussion of the activities of management.**

During the month of April 2026, management continued overseeing corporate activities, which focused primarily on development and marketing of the AGENTA, NARA, MINDLEAP and MUJN products and working on financial reporting activities. Management was also engaged in preparing and filing audited year-end financial statements.

On April 14, 2026 the Issuer announced by the way of news release that it entered into a non-binding Letter of Intent (the "LOI") dated April 13, 2026 with Ayla BioScience Inc. ("Ayla BioScience"), whereby the Company will acquire all of the issued and outstanding common shares of Ayla BioScience (the "Proposed Transaction"). Upon completion of the Proposed Transaction, the combined entity will continue the businesses of both PanGenomic Health and Ayla BioScience (the "Combined Business").

Headquartered in the United States, with operational presence in Colombia, Ayla BioScience is a vertically integrated biomanufacturing company focused on developing and commercializing advanced functional food, nutraceutical and plant-based bioactive products. Ayla BioScience leverages proprietary solid-state fermentation and dehydration technologies that enhance efficiency and preserve the molecular integrity of bioactive compounds.

PanGenomic Health and Ayla BioScience will leverage their combined expertise in the natural health industry to create a broad suite of products that provide consumers and health practitioners with access to personalized medicine tools and sustainable, high-value natural products.

Transaction Terms

The Proposed Transaction is expected to be completed by way of a share exchange, merger, amalgamation, arrangement or other similar form of transaction whereby the shareholders of Ayla BioScience will receive common shares in the capital of the Company in exchange for their shares in the capital of Ayla BioScience. The final structure and form of the Proposed Transaction remains subject to satisfactory tax, corporate and securities law advice for both the Company and Ayla BioScience and will be set forth in a definitive agreement (the "Definitive Agreement") to be entered into among the parties.

Under the terms of the LOI, the outstanding shares of the Company, including (i) any shares of the Company issuable upon the exercise or conversion of all options, warrants, convertible notes or other securities or instruments exercisable or convertible for shares of the Company outstanding at the time the Definitive Agreement is entered into, and (ii) any securities issued or issuable pursuant to the Company Offering (as defined below), will constitute between 15-20% of the outstanding shares of the Combined Business. The outstanding shares of Ayla BioScience, including any shares of Ayla BioScience issuable upon the exercise or conversion of all options, warrants, convertible notes or other securities or instruments exercisable or convertible for shares of Ayla BioScience outstanding at the time the Definitive Agreement is entered into will be exchanged for common shares of the Combined Business constituting between 80-85% of the outstanding shares of the Combined Business. No finder's fee is expected to be paid in connection with the Proposed Transaction.

In conjunction with, or prior to the closing the Proposed Transaction, the Company intends to complete a private placement for gross proceeds of up to \$2,000,000 (the "Company Offering"). The terms of the Company Offering will be determined in the context of the market at a price not less than the maximum permitted discount to the market price of the Company shares as of today's date. Additional details with respect to the Company Offering will be provided once determined.

Management and Governance

Following completion of the Proposed Transaction, PanGenomic Health's existing management team will retain leadership of the Canadian parent company, and Ayla BioScience's existing management team will retain leadership of the US and Colombian subsidiary businesses. The composition of the board of directors of the Company upon completion of the Proposed Transaction will be finalized in the Definitive Agreement. Full details will be disclosed upon finalization and execution of the Definitive Agreement.

Conditions and Approvals

Completion of the Proposed Transaction is subject to standard conditions, including, but not limited to:

- The negotiation of definitive terms for the Proposed Transaction and the negotiation and execution of the Definitive Agreement;
- Completion of satisfactory due diligence;
- Receipt of all required regulatory, corporate, and shareholder approvals, including approval of the shareholders of Ayla BioScience and, if required, the shareholders of PanGenomic Health;
- Acceptance of the Proposed Transaction by the Canadian Securities Exchange (the "CSE");
- Completion of the Company Financing;
- Delivery of financial statements of both PanGenomic Health and Ayla BioScience as required under applicable securities laws and the policies of the CSE; and
- No material adverse changes in either party.

There can, however, be no assurance that the Proposed Transaction will be completed as proposed or at all. The parties expect to finalize and execute the Definitive Agreement by early May 2026, with closing currently targeted on or before May 31, 2026.

The Proposed Transaction is expected to constitute a "Fundamental Change" as defined and in accordance with CSE Policy 8 and will result in a change of control of the Company. Trading in the common shares of the Company was halted pending dissemination of this release. Upon execution of a Definitive Agreement, trading in the common shares of the Company is expected to be halted pending the review of the Proposed Transaction by the CSE and the filing of required documentation, in accordance with CSE Policy 8.

The Issuer's aforementioned news release can be viewed under the Issuer's profile on SEDAR (www.sedar.com). The Issuer's aforementioned news releases can also be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None Material.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None Material.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None Material.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None Material.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None Material.

8. **Describe the acquisition of new customers or loss of customers.**

None Material.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None Material.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None Material.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None Material.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the**

proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None Material.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None Material.

14. **Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
No Securities Were Issued During the Month of April 2026.			

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None Material.

16. **Provide details of any changes in directors, officers or committee members.**

None Material.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The trends and risks which are likely to impact the Issuer are detailed in the section named "Risk Factors" of the Issuer's Prospectus dated January 14, 2022, the Issuer Filing Statement dated July 13, 2022 and the Issuer's Management Discussion and Analysis dated June 30, 2025 (the "MD&A"), under the heading "Risk and Uncertainties". The Prospectus and Filing Statement can be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange. The MD&A can be viewed under the Issuer's profile on SEDAR+ (www.sedarplus.ca).

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2026.

Robert Nygren

Name of Director or Senior Officer

"Robert Nygren"

Signature

Executive Chair

Official Capacity

Issuer Details Name of Issuer PANGENOMIC HEALTH INC.	For Month Ended April 2026	Date of Report YYYY / MM / DD 2026 / 05 / 06
Issuer Address 200 - 1575 W. Georgia St.		
City/Province/Postal Code Vancouver, BC V6G 2V3	Issuer Fax No. N/A	Issuer Telephone No. 778-743-4642
Contact Name Maryam Marissen	Contact Position CEO	Contact Telephone No. 778-743-4642
Contact Email Address maryam@pangenomic.com	Web Site Address www.pangenomic.com	